drugset / Trial / NCT05061732

Helicobacter Pylori Eradication and Follow-up

NCT05061732

Phase 4 Unknown 4447 enrolled Shanghai Zhongshan Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This randomized controlled clinical trial will estimate the eradication efficacy of different therapy for Helicobacter pylori treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.

Timeline

Start
2021-09-30
Primary completion
2026-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g
Subject Bismuth Potassium Citrate Unknown 0.6 g
Subject Clarithromycin Small molecule 0.5 g
Subject Doxycycline Small molecule 0.1 g
Subject Levofloxacin Small molecule 0.5 g
Subject Metronidazole Small molecule 0.4 g
Subject Rabeprazole Small molecule 20 mg
Comparator Tetracycline Unknown 0.5 g